{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T05:04:50Z","timestamp":1764133490972,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.pupt.2021.102080","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:43:00Z","timestamp":1632778980000},"page":"102080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps"],"prefix":"10.1016","volume":"71","author":[{"given":"Rui","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-3819","authenticated-orcid":false,"given":"Ryan","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7099-9396","authenticated-orcid":false,"given":"Justin","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7538-3005","authenticated-orcid":false,"given":"Rik","family":"Schoemaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianbin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurelie","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaohong","family":"She","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Vadhavkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1573-1194","authenticated-orcid":false,"given":"Melissa","family":"Cheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-500X","authenticated-orcid":false,"given":"Kit","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore A.","family":"Omachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7695-3498","authenticated-orcid":false,"given":"Wendy S.","family":"Putnam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica L.","family":"Quartino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4049\/jimmunol.158.3.1438","article-title":"Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody","volume":"158","author":"MacGlashan","year":"1997","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.pupt.2021.102080_bib2","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.pupt.2021.102080_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jaci.2003.10.003","article-title":"Omalizumab treatment downregulates dendritic cell FcepsilonRI expression","volume":"112","author":"Prussin","year":"2003","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.anai.2009.11.022","article-title":"The effects of omalizumab on IgE-induced cytokine synthesis by asthmatic airway smooth muscle cells","volume":"104","author":"Roth","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.pupt.2021.102080_bib5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1164\/rccm.200312-1651OC","article-title":"Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma","volume":"170","author":"Djukanovic","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000070434","article-title":"Immunological and clinical changes in allergic asthmatics following treatment with omalizumab","volume":"131","author":"Noga","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.pupt.2021.102080_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000350852","article-title":"Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma","volume":"161","author":"Takaku","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.pupt.2021.102080_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"10.1016\/j.pupt.2021.102080_bib9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.jaci.2015.09.005","article-title":"Association of periostin expression with eosinophilic inflammation in nasal polyps","volume":"136","author":"Wang","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1398-9995.2010.02448.x","article-title":"Mucosal tissue polyclonal IgE is functional in response to allergen and SEB","volume":"66","author":"Zhang","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.pupt.2021.102080_bib11","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.pupt.2021.102080_bib12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2500\/108854196778662255","article-title":"The clinical relationship of nasal polyps to asthma","volume":"17","author":"Larson","year":"1996","journal-title":"Allergy Asthma Proc"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2500\/ajra.2009.23.3284","article-title":"Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy","volume":"23","author":"Pearlman","year":"2009","journal-title":"Am J Rhinol Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2021.102080_bib14","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/00005537-200405000-00027","article-title":"Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial","volume":"114","author":"Ragab","year":"2004","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2500\/105065887781693420","article-title":"Nasal polyps: epidemiology, pathology, immunology, and treatment","volume":"1","author":"Settipane","year":"1987","journal-title":"Am J Rhino"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/0194599820939964","article-title":"Role of biologics in chronic rhinosinusitis with nasal polyposis: state of the art review","volume":"164","author":"Kim","year":"2021","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"10.1016\/j.pupt.2021.102080_bib17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2500\/ajr.2007.21.3060","article-title":"The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study","volume":"21","author":"Penn","year":"2007","journal-title":"Am J Rhinol"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4193\/Rhino09.144","article-title":"A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis","volume":"48","author":"Pinto","year":"2010","journal-title":"Rhinology"},{"issue":"Suppl 4","key":"10.1016\/j.pupt.2021.102080_bib19","doi-asserted-by":"crossref","first-page":"O11","DOI":"10.1186\/2045-7022-5-S4-O11","article-title":"Influence of the diagnosis chronic rhinosinusitis on asthma response to omalizumab in severe, uncontrolled asthmatics","volume":"5","author":"Sintobin","year":"2015","journal-title":"Clinical Transl Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2021.102080_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.anai.2013.01.024","article-title":"Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma","volume":"110","author":"Tajiri","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"9","key":"10.1016\/j.pupt.2021.102080_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1136\/thx.2010.152835","article-title":"Efficacy of omalizumab in the treatment of nasal polyps","volume":"66","author":"Vennera Mdel","year":"2011","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib23","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.pupt.2021.102080_bib24","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2125.2006.02803.x","article-title":"A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab","volume":"63","author":"Hayashi","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.dmpk.2015.12.003","article-title":"Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion","volume":"31","author":"Honma","year":"2016","journal-title":"Drug Metab Pharmacokinet"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib26","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1365-2125.2011.03962.x","article-title":"Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE","volume":"72","author":"Lowe","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2125.2009.03401.x","article-title":"Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma","volume":"68","author":"Lowe","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput Methods Programs Biomed"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"10.1016\/j.pupt.2021.102080_bib30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00151829-200403030-00006","article-title":"Omalizumab: a review of its use in the management of allergic asthma","volume":"3","author":"Bang","year":"2004","journal-title":"Treat Respir Med"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib31","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3565(25)21215-0","article-title":"Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys","volume":"279","author":"Fox","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pupt.2021.102080_bib32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.pupt.2021.102080_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553921000924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:30:41Z","timestamp":1761082241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553921000924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":33,"alternative-id":["S1094553921000924"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102080","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2021.102080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102080"}}